These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10421474)

  • 1. On the physiological role(s) of the paraoxonases.
    La Du BN; Aviram M; Billecke S; Navab M; Primo-Parmo S; Sorenson RC; Standiford TJ
    Chem Biol Interact; 1999 May; 119-120():379-88. PubMed ID: 10421474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein.
    Graham A; Hassall DG; Rafique S; Owen JS
    Atherosclerosis; 1997 Dec; 135(2):193-204. PubMed ID: 9430369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress.
    Liu Y; Mackness B; Mackness M
    Free Radic Biol Med; 2008 Sep; 45(6):743-8. PubMed ID: 18585453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.
    Primo-Parmo SL; Sorenson RC; Teiber J; La Du BN
    Genomics; 1996 May; 33(3):498-507. PubMed ID: 8661009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.
    Shih DM; Gu L; Xia YR; Navab M; Li WF; Hama S; Castellani LW; Furlong CE; Costa LG; Fogelman AM; Lusis AJ
    Nature; 1998 Jul; 394(6690):284-7. PubMed ID: 9685159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does paraoxonase play a role in susceptibility to cardiovascular disease?
    Aviram M
    Mol Med Today; 1999 Sep; 5(9):381-6. PubMed ID: 10462749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.
    Draganov DI; Stetson PL; Watson CE; Billecke SS; La Du BN
    J Biol Chem; 2000 Oct; 275(43):33435-42. PubMed ID: 10931838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
    Draganov DI; Teiber JF; Speelman A; Osawa Y; Sunahara R; La Du BN
    J Lipid Res; 2005 Jun; 46(6):1239-47. PubMed ID: 15772423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism.
    Costa LG; Li WF; Richter RJ; Shih DM; Lusis A; Furlong CE
    Chem Biol Interact; 1999 May; 119-120():429-38. PubMed ID: 10421480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity.
    Kuo CL; La Du BN
    Drug Metab Dispos; 1998 Jul; 26(7):653-60. PubMed ID: 9660847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
    Aviram M; Rosenblat M; Billecke S; Erogul J; Sorenson R; Bisgaier CL; Newton RS; La Du B
    Free Radic Biol Med; 1999 Apr; 26(7-8):892-904. PubMed ID: 10232833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic inflammation, intestine, and paraoxonase-1.
    Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
    Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.
    Boemi M; Leviev I; Sirolla C; Pieri C; Marra M; James RW
    Atherosclerosis; 2001 Mar; 155(1):229-35. PubMed ID: 11223446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity].
    Josse D; Masson P
    Ann Pharm Fr; 2001 Apr; 59(2):108-18. PubMed ID: 11320335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis?
    La Du BN
    Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):467-8. PubMed ID: 11304457
    [No Abstract]   [Full Text] [Related]  

  • 16. A long and winding road: defining the biological role and clinical importance of paraoxonases.
    James RW
    Clin Chem Lab Med; 2006; 44(9):1052-9. PubMed ID: 16958594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of protection against oxidative modification of LDL by avian HDL.
    Mackness B; Durrington PN; Mackness MI
    Biochem Biophys Res Commun; 1998 Jun; 247(2):443-6. PubMed ID: 9642147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities.
    Aviram M; Hardak E; Vaya J; Mahmood S; Milo S; Hoffman A; Billicke S; Draganov D; Rosenblat M
    Circulation; 2000 May; 101(21):2510-7. PubMed ID: 10831526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
    Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
    Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraoxonases: metabolic role and pharmacological projection.
    Moya C; Máñez S
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):349-359. PubMed ID: 29404699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.